Dr. Elisabeth Buchdunger
''Dr. Elisabeth Buchdunger of Novartis Pharma AG, Switzerland received her PhD in Biology from the University of Freiburg, Germany. Following postdoctoral positions at the Friedrich-Miescher Institute, Basel, and the University of Basel, she joined the Oncology Research group at Ciba-Geigy (now Novartis) in 1990. Working in the signal transduction field, she established cellular assays for the identification and characterization of protein kinase inhibitors. She contributed to the development of several protein kinase inhibitors, including Glivec. She is the preclinical research representative in the International Project Team for Glivec and has gained a practical understanding of both Research & Development aspects at the pharmaceutical process. She is one of the recipients of the Bruce-Cain Memorial Award (2002) from the American Association for Cancer Research (AACR).''
Extract of http://www.biofinland.fi/2003/biographies.htm
|Chronic Myeloid Leukemia||